Navigation Links
Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
Date:6/21/2013

New York, New York (PRWEB) June 21, 2013

As Januvia pancreatic cancer lawsuit claims continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that a new investigation by the British Medical Journal is raising serious questions about the safety of type 2 diabetes drugs like Januvia. According to the June 10th report, previously unpublished data indicate that incretin mimetics, the class of medications that includes Januvia, may have harmful effects on the pancreas which were downplayed by their manufacturers. The report also asserts that investigators were denied access to raw data that might have resolved doubts about the safety of Januvia and other incretin mimetics.*

"The findings of this investigation would appear to lend weight to claims made by plaintiffs who have filed Januvia lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Januvia pancreatic cancer, Januvia pancreatitis or Januvia thyroid cancer.

Januvia Lawsuits
Court documents indicate that Merck & Co. has been named in a number of Januvia lawsuits that allege the drug caused users to develop pancreatic cancer, pancreatitis or thyroid cancer. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25, 2013, regarding the proposed establishment of a multidistrict litigation for all federally-filed lawsuits involving Januvia and other incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

The U.S. Food & Drug Administration (FDA) announced in March that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas.** Earlier this month, the American Diabetes Association called for an independent review of all incretin mimetics to provide clarity to patients and health care providers in light of the recent controversy.***

The British Medical Journal investigation is not the first time concerns have arisen regarding the possible pancreatic side effects associated with Januvia and similar drugs. In 2009, a caution regarding a potential Januvia pancreatitis risk was added to the drug’s label after the FDA became aware of 88 post-marketing cases of acute pancreatitis in patients taking the drug.**** In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer. Two cases of thyroid cancer were also reported in the patients who took Januvia.****

Alleged victims of Januvia pancreatic cancer, thyroid cancer or pancreatitis may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013
**fda.gov/Drugs/DrugSafety/ucm343187.htm
***diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html, ADA, June 10, 2013
****fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm; September 25, 2009
*****gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuit2013.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10858585.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
2. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
3. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
6. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
7. DrugRisk Announces Addition of Januvia Cancer Resource Center
8. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
9. Pancreatic Cancer Survivor and Author Bob Brown Releases Highly Anticipated New Book "Ride of My Life"
10. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
11. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... California health startup Pegara announced ... helps people assess their risk of developing Alzheimer’s disease. Using a questionnaire based ... “Risk Reduction Score™” that summarizes how their lifestyle choices may affect their chances ...
(Date:5/3/2016)... Yorba Linda, CA (PRWEB) , ... May 03, ... ... exponential enrichment) is a process that selects DNA or RNA from a random ... ligands—called aptamers—could potentially be used as drugs or diagnostic agents. SELEX selection is ...
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking ... her with one on her shoulder and one on her arm. But she got ... of years of mitral valve prolapse. , The valves of the heart wouldn’t close ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a leader in ... a three hospital system in South Carolina, to provide its secure mobile communication ... that enhances communication, drives workflow efficiencies and improves provider and patient satisfaction,” said ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Each year, about ... cause of death across the United States and account for one death every four ... impairments or are permanently disabled. HCR ManorCare is launching a video series called “Your ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... Report provides a basic overview of the industry ... which the surgical mesh report explores into the ... Complete report on Surgical Mesh market spread ... 98 tables and figures is available at ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... company, today announced data from the first cohort ... clinical trial (the OVATION Study) combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  In the first three ...
Breaking Medicine Technology: